FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to use of valproic acid or its pharmaceutically acceptable salt for treating or preventing a pathological condition, associated with excessive deposition of fibrin and/or formation of thrombi, said treatment involves the introduction of at least one dose of valproic acid or its pharmaceutically acceptable salt to the patient so that the maximum concentration of valproic acid or its salt and/or its metabolite in plasma (Cmax) is observed in the patient for a period of time, which ranges from four hours to one hour after achieving maximum plasma concentration (PAm-1) in patient (Cmax).
EFFECT: disclosed are compounds and compositions for treating or preventing pathological conditions associated with excessive deposition of fibrin and/or formation of thrombi.
17 cl, 3 ex, 1 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS WITH DEFERRED RELEASE CONTAINING VALPROIC ACID AND THEIR USE | 2017 |
|
RU2760304C2 |
| METHODS OF TREATING OR PREVENTING THROMBOSIS OR EMBOLISM | 2011 |
|
RU2611662C2 |
| COMPOSITION FOR INHIBITING SYNTHESIS OF 5-HT2B AGONIST AND METHODS OF USE THEREOF | 2017 |
|
RU2746000C2 |
| ANTITHROMBOTIC COMPOUND | 2012 |
|
RU2604733C2 |
| THROMBOLYTIC AGENTS | 1995 |
|
RU2142799C1 |
| TREATMENT OF HYPERKINETIC MOTOR DISORDERS | 2015 |
|
RU2753740C2 |
| INJECTION OF DEUTERATED CFTR AMPLIFIERS | 2016 |
|
RU2761344C2 |
| SOLID COMPOSITIONS BASED ON BETAHISTINE FOR ORAL ADMINISTRATION WITH NON-PULSATING PROLONGED RELEASE | 2018 |
|
RU2774644C2 |
| METHODS AND COMPOSITIONS WITH APPLICATION OF IMMUNOMODELLING COMPOUNDS IN COMBINED TREATMENT | 2007 |
|
RU2426542C2 |
| NEW COMPOSITIONS AND METHODS | 2018 |
|
RU2767410C2 |
